Cardiac transthyretin amyloidosis

Heart

Volumn 98, Issue 21, 2012, Pages 1546-1554

  Dungu, Jason N ^a,b   Anderson, Lisa J ^a   Whelan, Carol J ^b   Hawkins, Philip N ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [6 (2 CARBOXYPYRROLIDIN 1 YL) 6 OXOHEXANOYL]PYRROLIDINE 2 CARBOXYLIC ACID; ALANINE; ALN TTR 01; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; AMYLOID PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTISENSE OLIGONUCLEOTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTEDRONATE TECHNETIUM TC 99M; DIFLUNISAL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISIS TTRRX; ISOLEUCINE; LOOP DIURETIC AGENT; MEDRONATE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; PLACEBO; PREALBUMIN; PROLINE DERIVATIVE; PYROPHOSPHATE TECHNETIUM TC 99M; SERUM AMYLOID P; SERUM AMYLOID P ANTIBODY; SMALL INTERFERING RNA; TAFAMIDIS; THREONINE; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE;

AFRICAN CARIBBEAN; AMINO ACID SUBSTITUTION; ANGINA PECTORIS; ARTIFICIAL HEART PACEMAKER; ASCITES; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CAUCASIAN; CENTRAL VENOUS PRESSURE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DEFIBRILLATION; DIAGNOSTIC TEST; DIASTOLIC HEART FAILURE; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DYSPNEA; EART AMYLOID LIGHT CHAIN AMYLOIDOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FAINTNESS; FAMILIAL AMYLOID POLYNEUROPATHY; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEART AMYLOIDOSIS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE BIOPSY; HEART PALPITATION; HEART SCINTISCANNING; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART TRANSPLANTATION; HEART TRANSTHYRETIN AMYLOIDOSIS; HEART VENTRICLE HYPERTROPHY; HEPATOMEGALY; HUMAN; KIDNEY DYSFUNCTION; LEG EDEMA; LIVER TRANSPLANTATION; NONHUMAN; OFF LABEL DRUG USE; PATIENT REFERRAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WILD TYPE;

AMYLOIDOSIS; CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MUTATION; PREALBUMIN; PROGNOSIS;

EID: 84867909224     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-301924     Document Type: Review

References (68)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
2. Wechalekar AD, Gillmore JD, Gibbs SDJ, et al. 25 Years Of amyloidosis in the UK- A single centre experience of 5100 patients [abstract]. XIIIth International Symposium on Amyloidosis. 2012.
3. Blake CC, Geisow MJ, Oatley SJ, et al. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol 1978;121:339-56.
4. Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160-84.
5. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-23.
6. Sacchettini JC, Kelly JW. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov 2002;1:267-75.
7. Altland K, Banzhoff A. Separation by hybrid isoelectric focusing of normal human plasma transthyretin (prealbumin) and a variant with a methionine for valine substitution associated with familial amyloidotic polyneuropathy. Electrophoresis 1986;7:529-33.
8. Dubrey S, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-57.
9. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-12.
10. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-10.
11. Westermark P, Sletten K, Johansson B, et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 1990; 87:2843-5.
12. Westermark P, Bergström J, Solomon A, et al . Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 2003;10(Suppl 1):48-54.
13. Ueda M, Horibata Y, Shono M, et al. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol 2011;24:1533-44.
14. Kyle RA, Spittell PC, Gertz MA, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996; 101:395-400.
15. Ng B, Connors LH, Davidoff R, et al . Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-9.
16. Cornwell GG 3rd, Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 1983;75:618-23.
17. Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008;40:232-9.
18. Sekijima Y, Uchiyama S, Tojo K, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 2011:42:1785-91.
19. Kyle RA, Gertz MA, Linke RP. Amyloid localized to tenosynovium at carpal tunnel release. Immunohistochemical identification of amyloid type. Am J Clin Pathol 1992;97:250-3.
20. Gorevic PD, Prelli FC, Wright J, et al. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest 1989;83:836-43.
21. Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet 1990;47:127-36.
22. Jacobson DR, Pastore R, Pool S, et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996;98 :236-8.
23. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-73.
24. Buxbaum J, Jacobson DR, Tagoe C, et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol 2006;47:1724-5.
25. Connors L, Prokaeva T, Lim A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009;158:607-14.
26. Buxbaum J, Alexander A, Koziol J, et al. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and cardiovascular Health (CHS) studies. Am Heart J 2010;159:864-70.
27. Wallace MR, Dwulet FE, Conneally PM, et al. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest 1986;78:6-12.
28. Staunton H, Dervan P, Kale R, et al. Hereditary amyloid polyneuropathy in north west Ireland. Brain 1987;110:1231-45.
29. Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012;33:1120-7.
30. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-91.
31. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-9.
32. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107:904-6.
33. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005;95:535-7.
34. Dungu J, Sattianayagam PT, Whelan CJ, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin Isoleucine 122 (V122I) type in Afro-Caribbean patients. Am Heart J 2012;164:72-9.
35. Heldestad V, Wiklund U, Hörnsten R, et al. Comparison of quantitative sensory testing and heart rate variability in Swedish Val30Met ATTR. Amyloid 2011:18:183-90.
36. Reyners A, Hazenberg BP, Reitsma WD, et al. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 2002;23:157-61.
37. Falk RH, Plehn JF, Deering T, et al. Sensitivity and Specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 1987;59 :418-22.
38. MacIver DH, Townsend M. A novel mechanism of heart failure with normal ejection fraction. Heart 2007;94:446-9.
39. Koyama J, Ray-Sequin PA, Davidoff R, et al. Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol 2002;89 :1067-71.
40. Bellavia D, Pellikka PA, Abraham TP, et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and No evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 2008;101:1039-45.
41. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003;107:2446-52.
42. Sun JP, Stewart WJ, Yang XS, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by twodimensional strain imaging echocardiography. Am J Cardiol 2009;103:411-15.
43. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93.
44. Maceira AM, Prasad SK, Hawkins PN, et al . Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008;10:54.
45. Perugini E, Rapezzi C, Piva T, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92:343-9.
46. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51:1022-30.
47. Dungu J, Whelan C, Gibbs S, et al. Patterns of late gadolinium enhancement predict survival in cardiac amyloidosis: a systematic review of 95 cases with AL or TTR type [abstract]. J Am Coll Cardiol 2012; 59:1225.
48. Benson MD, Teague SD, Kovacs R, et al. Rate of progression of transthyretin amyloidosis. Am J Cardiol 2011;108:285-9.
49. Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002;11:649-55.
50. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323 :508-13.
51. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122 :78-84.
52. Perugini E, Guidalotti PL, Salvi F, et al . Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2- propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.
53. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4 :659-70.
54. Glaudemans AW, Slart RH, Zeebregts CJ, et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging 2009;36:702-14.
55. Puille M, Altland K, Linke RP, et al . 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging 2002;29:376-9.
56. Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957-9.
57. Ikeda S, Sekijima Y, Tojo K, et al . Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis. Amyloid 2011;18 :211-15.
58. Ando Y, Tanaka Y, Nakazato M, et al . Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation. Biochem Biophys Res Commun 1995; 211 :354-8.
59. Buxbaum J, Anan I, Suhr O. Serum transthyretin levels in Swedish TTR V30M carriers. Amyloid 2010;17:83-5.
60. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5.
61. Suhr OB, Anan I, Backman C, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008;263:294-301.
62. Berk JL, Dyck PJ, Obici L, et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid 2011;18(Suppl 1):191-2.
63. Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: from delineating the molecular mechanism of Aggregation Linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012;421:185-203.
64. European Medicines Agency (EMA). European Public Assessment Report . EMA website. http://www.ema.europa.eu/docs/en-GB/document
65. Sah D. Phase I safety, pharmacokinetic and pharmacodynamics results for ALNTTR01, a novel RNAi therapeutic for the treatment of transthyretin amyloidosis. VIIIth International Symposium on Familial Amyloid Polyneuropathy . 2011.
66. Benson MD, Pandey S, Witchell D, et al . Antisense oligonucleotide therapy for TTR amyloidosis. Amyloid 2011;18(Suppl 1):55.
67. Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-9.
68. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93-7.